Overview
SS-31, also known as Bendavia or elamipretide, is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It is designed to selectively bind to cardiolipin, a phospholipid exclusively found in the inner mitochondrial membrane. By targeting this location, SS-31 aims to improve mitochondrial function and reduce oxidative stress.
The peptide's primary purpose is to enhance energy production within cells by optimizing the structure and function of mitochondria. Dysfunctioning mitochondria are implicated in aging and several diseases, making SS-31 a therapeutic candidate for a wide range of conditions.
Mechanism of Action
SS-31 binds to cardiolipin, which is critical for maintaining the structure of the mitochondrial inner membrane and the efficiency of the electron transport chain. Binding of SS-31 to cardiolipin stabilizes the interaction between cardiolipin and proteins of the electron transport chain, improving their efficiency. This, in turn, enhances ATP production and reduces the generation of reactive oxygen species (ROS).
Furthermore, SS-31 can reduce mitochondrial swelling and prevent the opening of the mitochondrial permeability transition pore (mPTP), a critical event in cell death pathways. By preventing mPTP opening, SS-31 helps to preserve mitochondrial integrity and cell survival under stress conditions.
Key Benefits
- Reduces oxidative stress
- Enhances mitochondrial ATP production
- Protects against mitochondrial dysfunction
- Improves cellular energy levels
- May improve cardiovascular function
Research & Indications
Research indicates that SS-31 has potential therapeutic benefits in various conditions associated with mitochondrial dysfunction. Studies have explored its efficacy in treating heart failure, ischemia-reperfusion injury, and neurodegenerative diseases. Animal studies and clinical trials suggest that SS-31 can improve cardiac output, reduce infarct size, and enhance exercise tolerance.
Furthermore, SS-31 has shown promise in preclinical models of Alzheimer's disease and Parkinson's disease, where it reduced oxidative damage and improved mitochondrial function in neuronal cells. Clinical trials are ongoing to evaluate the safety and efficacy of SS-31 in these and other conditions.
Dosing Protocols
Disclaimer: The following dosing information is not medical advice. Consult with a qualified healthcare professional before using SS-31 or any other peptide.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Mitochondrial Support | 5-10 mg | 2-3 times per week | SubQ |
Supplies Needed
For an 8-16 week protocol:
- Peptide Vials: 4-10 vials of 10mg each
- Insulin Syringes (U-100): Approximately 10-20 per week, depending on frequency of injections
- Bacteriostatic Water: 2-3 × 10mL bottles
- Alcohol Swabs: One for vial + one for injection site daily
Side Effects & Safety
SS-31 is generally considered safe, but some common side effects may include injection site reactions (redness, swelling, or pain). Less common side effects could potentially include headache or mild gastrointestinal discomfort. Clinical trials have not reported significant adverse effects to date.
Contraindications: Individuals with known hypersensitivity to the peptide or any of its components should avoid SS-31. As with any investigational peptide, caution is advised for pregnant or breastfeeding women.
Storage & Handling
SS-31 should be stored in lyophilized form at -20°C until reconstitution. Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2-8°C and used within a few weeks. Avoid freezing reconstituted solutions.